Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 02, 2023	Apr. 03, 2022
Revenue from External Customer [Line Items]
Revenues		$ 18,282	$ 25,661
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	17,971	25,323
Business Innovation Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	310	338
Pfizer CentreOne [Member] | Business Innovation Segment [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	306	338
Pfizer Ignite [Member] | Business Innovation Segment [Member]
Revenue from External Customer [Line Items]
Revenues		4	0
Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenue - Alliance revenues		2,060	2,314
Primary Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		11,505	18,851
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		4,069	1,470
Primary Care [Member] | Comirnaty direct sales and alliance revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	3,064	13,227
Primary Care [Member] | Eliquis alliance revenues and direct sales [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,874	1,793
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,593	1,565
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		167	1
Primary Care [Member] | Premarin family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		112	102
Primary Care [Member] | BMP2 [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		86	67
Primary Care [Member] | FSME/IMMUN-TicoVac [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		45	42
Primary Care [Member] | Nimenrix [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		40	77
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		456	507
Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		3,612	3,505
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		686	612
Specialty Care [Member] | Sulperazon [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		320	210
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		237	372
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		199	280
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		178	135
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		150	125
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		147	80
Specialty Care [Member] | Ig Portfolio Products [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	126	107
Specialty Care [Member] | Zavicefta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		116	104
Specialty Care [Member] | BeneFIX [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		109	112
Specialty Care [Member] | Medrol [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		93	76
Specialty Care [Member] | Oxbryta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		71	0
Specialty Care [Member] | Somavert [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		66	68
Specialty Care [Member] | ReFacto AF/Xyntha [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		60	66
Specialty Care [Member] | Fragmin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		58	70
Specialty Care [Member] | Vfend [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		51	65
Specialty Care [Member] | All other Anti-infectives [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		374	381
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		569	643
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,855	2,967
Oncology [Member] | Ibrance [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,144	1,237
Oncology [Member] | Inlyta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		259	234
Oncology [Member] | Xtandi alliance revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		258	268
Oncology [Member] | Bosulif [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		150	128
Oncology [Member] | Zirabev [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		129	147
Oncology [Member] | Ruxience [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		114	124
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		112	72
Oncology [Member] | Xalkori [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		111	127
Oncology [Member] | Retacrit [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		93	115
Oncology [Member] | Bavencio Alliance Revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		85	67
Oncology [Member] | Aromasin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		77	62
Oncology [Member] | Besponsa [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		58	51
Oncology [Member] | Sutent [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		50	114
Oncology [Member] | Braftovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	49	48
Oncology [Member] | Mektovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		40	40
Oncology [Member] | Trazimera [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		34	52
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		$ 92	$ 81

[1] See Note 1A in our 2022 Form 10-K for information about our recent organizational changes within Biopharma. See Note 13A above for information about Business Innovation. Prior-period financial information has been revised to reflect the current period presentation.

[2] PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($5 million and $47 million for the first quarters of 2023 and 2022, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships.

[3] Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. See footnote (e) below.

[4] Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig.

[5] Erbitux® is a registered trademark of ImClone LLC.